Skip to main content
Premium Trial:

Request an Annual Quote

Bruker, AutoGenomics, PerkinElmer, GE Healthcare, American Peptide, AnaSpec, Novus

Spike in Bruker Q2 Revs
Bruker announced this week a 30.6 percent increase in revenues for its second quarter ended June 30.
For the quarter, the company posted receipts of $311.5 million, compared to $238.3 million a year ago. Currency effects contributed 12 percentage points to the results.
Profits rose 22.8 percent to $21.7 million, compared to $17.7 million a year ago. During the second quarter of 2008, Bruker repaid $158 million of debt related to its acquisition
of Bruker BioSpin in February. Its net debt position as of June 30 was $110.4 million.
In a statement, Bill Knight, CFO of Bruker said, while the global market environment has become increasingly challenging, “we are optimistic that our various medium-term growth and margin initiatives will continue our positive profitability trends of the last three years.”
The company’s research and development spending climbed to $36.5 million, up from $27.7 million a year ago. The company reported cash and short-term investments of $131.8 million as of June 30.

AutoGenomics Files IPO
Microarray firm AutoGenomics filed last week for an initial public offering.
The number of shares and share price has not yet been determined, but in its filing with the US Securities and Exchange Commission, the Carlsbad, Calif.,-based company said the aggregate offering price will be limited to a maximum of $86.3 million.
The company intends to list on the Nasdaq Global Market under ticker symbol AGMX.
JP Morgan Securities is acting as the sole book-running manager for the deal. Deutsche Bank Securities is co-lead manager, and Pacific Growth Equities and Robert W. Baird are acting as co-managers.
AutoGenomics’ lead technology is the Infiniti system, a microarray-based multiplexing molecular diagnostic platform used to assess proteomic and genomic biomarkers. The instrument received FDA 501(k) clearance for commercial sale in February 2007. Four tests developed by AutoGenomics have also received FDA clearance: a test for warfarin sensitivity and tests for Factor II, Factor V and Factor II-V measuring an individual’s risk for the development of blood clots.
“We believe that the versatility of our system to run the broad menu of tests that we currently offer and are developing will facilitate the acceptance and rapid adoption of our system and reduce the need for multiple testing technologies, platforms and specialized technicians in the laboratory,” AutoGenomics said in its filing. “Our system is cost-effective, easy to use, highly sensitive, and designed to test for multiple biomarkers on the same sample simultaneously.”
In 2007, the company posted $1.6 million in sales and recorded a loss of $9.3 million. It has $9.3 million in cash and cash equivalents as of March 31.

PerkinElmer Q2 Revs Up 21 Percent, Profit Slides Almost 30 Percent
PerkinElmer last week reported a 20.8 percent increase in its sales for the second quarter.
Receipts for the three months ended June 29 rose to $528.6 million, up from $437.3 million during the year ago period. Currency exchange and acquisition each contributed 5 percentage points to the increase, the company said in a statement.
Life and Analytical Sciences revenues grew 21.7 percent to $397.1 million from $326.3 million a year ago. Optoelectronics revenues rose 18.5 percent to $131.6 million from $111.0 million during the second quarter of 2007.
Net income slid 29.6 percent to $23.7 million from $33.7 million during the quarter. SG&A expenses rose to $143 million from $109.4 million a year ago, while research and development spending climbed to $29.9 million from $27.3 million a year ago.
The company reported $193.5 million in cash and cash equivalents as of June 29.

Amid Reorganization, GE Healthcare Folded into Technology Infrastructure Unit
General Electric announced last week that it is streamlining its unit structure from six units down to four units. In the process, GE Healthcare will no longer operate as a standalone unit, but will be folded into the new GE Technology Infrastructure unit.
The reorganization is intended to align the businesses “for growth and efficiency,” the firm said in a statement.
The Healthcare business will join Aviation, Transportation, and Enterprise Solutions as components of the Technology Infrastructure unit, which will have revenues of nearly $90 billion. Vice Chairman John Rice will lead the unit.
In advance of the reorganization, former GE Healthcare CEO Joseph Hogan left the firm two weeks ago to take over as CEO of power and automation company ABB.
The other three units are GE Energy Infrastructure, GE Capital, and NBC Universal. GE said a couple of months ago that it intends to jettison its unit that includes household appliances, lighting, motors, and electrical distribution.

American Peptide, Parent Firm Bought by Otsuka
American Peptide said this week that its parent firm, Ito Life Sciences, will be acquired by Otsuka Chemical, effective Sept. 1. Itoham Foods currently owns Ito Life Sciences.
Financial terms of the deal were not disclosed. Ito Life Sciences of Shanghai, also a subsidiary of Ito Life Sciences, headquartered in Ibaraki, Japan, will also be purchased by Otsuka, based in Osaka, Japan, as part of the deal.
American Peptide said also that it is expanding its facilities in Vista and Sunnyvale, Calif.
“By operating as an enterprise of Otsuka Chemical, we will create new global networking opportunities as well as channel more financial resources to our production and manufacturing facilities,” Takahiro Ogata, president and COO of American Peptide, said in a statement.

Novus Labeling Antibodies with AnaSpec Dyes
AnaSpec and Novus Biologicals announced this week a licensing agreement allowing Novus to label its antibodies with AnaSpec’s HiLytePlus and HiLyte Fluor dyes.
The dyes are optimized for long wavelength biomarker testing.
Financial terms of the deal were not disclosed. 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.